Precision targeting of the plasminogen activator inhibitor‐1 mechanism increases efficacy of fibrinolytic therapy in empyema

Precision targeting of the plasminogen activator inhibitor‐1 mechanism increases efficacy of fibrinolytic therapy in empyema

Abstract Plasminogen activator inhibitor‐1 (PAI‐1) is an endogenous irreversible inhibitor of tissue‐type (tPA) and urokinase (uPA) plasminogen activators. PAI‐1‐targeted fibrinolytic therapy (PAI‐1‐TFT) is designed to decrease the therapeutic dose of tPA and uPA, attenuating the risk of bleeding an...

Full description

Bibliographic Details
Main Authors: Galina Florova, René A. Girard, Ali O. Azghani, Krishna Sarva, Ann Buchanan, Sophia Karandashova, Christian J. DeVera, Danna Morris, Mignote Chamiso, Kathleen Koenig, Douglas B. Cines, Steven Idell, Andrey A. Komissarov
Format: Article
Language:English
Published: Wiley 2021-05-01
Series:Physiological Reports
Subjects:
empyema
fibrinolytic therapy
molecular target
plasminogen activator inhibitor‐1
single chain tissue plasminogen activator
Online Access:https://doi.org/10.14814/phy2.14861

Internet

https://doi.org/10.14814/phy2.14861

Similar Items